Spots Global Cancer Trial Database for infliximab
Every month we try and update this database with for infliximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms | NCT02638701 | Aneurysm Stroke Vasculitis Tumor Necrosis ... | Infliximab | 18 Years - | University of California, San Francisco | |
| Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands | NCT00731536 | Hepatosplenic T... | No intervention | - | Centocor Ortho Biotech Services, L.L.C. | |
| A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors | NCT02136069 | Ulcerative Coli... | Etrolizumab Infliximab Placebo (IV) Placebo (Inject... | 18 Years - 80 Years | Hoffmann-La Roche | |
| Infliximab Efficacy, TDM and Serum TNFα Levels in Pediatric HSCT Recipients With aGVHD: Prospective Observational Study | NCT05362630 | Graft Versus Ho... Hematopoietic S... | - 18 Years | University of Pisa | ||
| Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease | NCT00325078 | Chronic Granulo... Crohn'S-like IB... Inflammatory Bo... | Infliximab | 10 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan | NCT03348046 | Rheumatoid Arth... | Biosimilar Infl... | 18 Years - | Hikma Pharmaceuticals LLC | |
| Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis | NCT04438382 | Hematopoietic a... Malignant Solid... Steroid-Refract... | Infliximab Intravenous Imm... Prednisone Methylprednisol... | 18 Years - | Eastern Cooperative Oncology Group | |
| PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | NCT05034536 | Metastatic Mela... | Pembrolizumab Infliximab Placebo Relatlimab Nivolumab | 18 Years - | Massachusetts General Hospital | |
| Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients | NCT03452501 | Inflammatory Bo... Crohn Disease Fistulizing Cro... Ulcerative Coli... | Infliximab | 18 Years - | Hikma Pharmaceuticals LLC | |
| Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis | NCT00432406 | Psoriatic Arthr... | Infliximab Etanercept | 18 Years - 70 Years | Chinese University of Hong Kong | |
| Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease | NCT05599347 | Crohn's Disease... Biological Subs... | Azithromycin Pi... Placebo | 18 Years - | Rambam Health Care Campus | |
| Infliximab Efficacy, TDM and Serum TNFα Levels in Pediatric HSCT Recipients With aGVHD: Prospective Observational Study | NCT05362630 | Graft Versus Ho... Hematopoietic S... | - 18 Years | University of Pisa | ||
| GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease | NCT00228839 | Graft vs Host D... | Infliximab | - 18 Years | Emory University | |
| A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors | NCT02136069 | Ulcerative Coli... | Etrolizumab Infliximab Placebo (IV) Placebo (Inject... | 18 Years - 80 Years | Hoffmann-La Roche | |
| Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands | NCT00731536 | Hepatosplenic T... | No intervention | - | Centocor Ortho Biotech Services, L.L.C. | |
| A Study of Infliximab for Treatment Resistant Major Depression | NCT00463580 | Depression | Infliximab Placebo | 25 Years - 60 Years | Emory University | |
| Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World" | NCT02878161 | Rheumatoid Arth... | methotrexate(ne... infliximab etanercept adalimumab leflunomide (pe... NSAIDs (permitt... Glucocorticoids... | 18 Years - 75 Years | Central South University | |
| Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension | NCT02743390 | Hypertension | Infliximab Saline | 35 Years - 65 Years | University of Campinas, Brazil | |
| GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease | NCT00228839 | Graft vs Host D... | Infliximab | - 18 Years | Emory University | |
| Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis | NCT00432406 | Psoriatic Arthr... | Infliximab Etanercept | 18 Years - 70 Years | Chinese University of Hong Kong | |
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05) | NCT00040885 | Anorexia Cachexia Fatigue Lung Cancer | infliximab docetaxel placebo | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients | NCT03452501 | Inflammatory Bo... Crohn Disease Fistulizing Cro... Ulcerative Coli... | Infliximab | 18 Years - | Hikma Pharmaceuticals LLC | |
| A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | NCT01804166 | Hepatosplenic T... | Infliximab Golimumab | - | Janssen Scientific Affairs, LLC | |
| Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients | NCT03452501 | Inflammatory Bo... Crohn Disease Fistulizing Cro... Ulcerative Coli... | Infliximab | 18 Years - | Hikma Pharmaceuticals LLC | |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer | NCT03819296 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Colitis Lung Non-Small ... Malignant Genit... Malignant Solid... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage 0 Lung Ca... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Best Practice Biospecimen Col... Endoscopic Proc... Fecal Microbiot... Infliximab Laboratory Biom... Prednisone Vedolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | NCT05034536 | Metastatic Mela... | Pembrolizumab Infliximab Placebo Relatlimab Nivolumab | 18 Years - | Massachusetts General Hospital | |
| Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer | NCT00112749 | Breast Cancer Fatigue | infliximab Clinical Assess... Self-report que... Immune Assessme... | 45 Years - 65 Years | Jonsson Comprehensive Cancer Center | |
| Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms | NCT02638701 | Aneurysm Stroke Vasculitis Tumor Necrosis ... | Infliximab | 18 Years - | University of California, San Francisco | |
| Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05) | NCT00040885 | Anorexia Cachexia Fatigue Lung Cancer | infliximab docetaxel placebo | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis | NCT05796245 | Arthritis, Rheu... Colitis, Ulcera... Crohn Disease Psoriasis | 15 Years - | Pfizer | ||
| Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis | NCT01793519 | Rheumatoid Arth... | Etanercept Infliximab Adalimumab Placebo | 18 Years - | Georgetown University | |
| Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer | NCT00112749 | Breast Cancer Fatigue | infliximab Clinical Assess... Self-report que... Immune Assessme... | 45 Years - 65 Years | Jonsson Comprehensive Cancer Center | |
| Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | NCT02126020 | Stevens-Johnson... Toxic Epidermal... Mucous Membrane... | topical inflixi... | 18 Years - 80 Years | Massachusetts Eye and Ear Infirmary | |
| A Study of Infliximab for Treatment Resistant Major Depression | NCT00463580 | Depression | Infliximab Placebo | 25 Years - 60 Years | Emory University | |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer | NCT03819296 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Colitis Lung Non-Small ... Malignant Genit... Malignant Solid... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage 0 Lung Ca... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Best Practice Biospecimen Col... Endoscopic Proc... Fecal Microbiot... Infliximab Laboratory Biom... Prednisone Vedolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | NCT04407247 | Colitis Lung Non-Small ... Malignant Genit... Malignant Solid... Melanoma | Infliximab Vedolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease | NCT00228839 | Graft vs Host D... | Infliximab | - 18 Years | Emory University | |
| A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | NCT01804166 | Hepatosplenic T... | Infliximab Golimumab | - | Janssen Scientific Affairs, LLC | |
| Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis | NCT04305145 | Melanoma Stage ... Melanoma Stage ... Skin Cancer Sta... Skin Cancer Sta... Drug-Induced Co... Drug Toxicity Immune-related ... | Infliximab Methylprednisol... Prednisone | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
